SecBot SecBot

PRAX drug pipeline

$328.13
+1.0% 1-day · Nov 13
Next catalyst
Dec 27, 2026
relutrigine PDUFA date · in 41 days
Typical move on FDA news
±2.4%
1-day, median of 9 events
IV rank
No data
No current options data
Rated drugs
9
2 bullish · 1 mixed · 6 neutral
Phase 3 trials
3
0 with results posted

Upcoming catalysts

4 dated
  1. Dec 27, 202641d
    relutrigine
    PDUFA date · SCN2A and SCN8A developmental and epileptic encephalopathies
  2. Dec 2026
    1.0mg/kg/day PRAX-562
    Phase 3 primary completion
  3. Jan 2027
    40 mg/day vormatrogine for 12 weeks
    Phase 3 primary completion
  4. Jan 29, 202774d
    ulixacaltamide
    PDUFA date · Essential Tremor

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/PDUFA (NDA under priority review)
Time to marketPDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.

relutrigine Updated Nov 13

41days
Next catalyst
PDUFA date · Dec 27, 2026 · SCN2A and SCN8A developmental and epileptic encephalopathies
What to watch

The next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.

Bull case
  • Relutrigine has Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA, signaling strong agency interest and potential priority review benefits.
  • The Phase 2 EMBOLD study was stopped early for efficacy by the Data Monitoring Committee, and positive results formed the basis of the NDA submission with priority review.
  • No approved therapy specifically targets SCN2A/SCN8A developmental and epileptic encephalopathies, positioning relutrigine for potential first-in-class / first-in-disease status if approved.
Bear case
  • The FDA extended the original PDUFA by three months (from September to December 2026), which could signal review complexity or lingering safety/efficacy questions. The extension was attributed broadly to FDA staffing issues, but uncertainty remains.
  • The company is pre-revenue with no approved products; if relutrigine receives a Complete Response Letter (CRL), the stock would face significant downside given its ~$8B+ market cap already prices in approval.
  • The EMERALD study in broad DEEs (topline due Q4 2026) is a separate readout that could disappoint, and relutrigine's label may be initially limited to narrow SCN2A/SCN8A populations.
▲ bullish
Impact
PhaseFiled/NDA under FDA review (PDUFA January 29, 2027)
Time to marketIf approved, launch is anticipated in early 2027, shortly after the January 29, 2027 PDUFA date.

ulixacaltamide ulixacaltamide hydrochloride Updated Nov 13

74days
Next catalyst
PDUFA date · Jan 29, 2027 · Essential Tremor
What to watch

The next hard catalyst is the PDUFA decision on January 29, 2027, roughly 2.5 months away. An approval would make ulixacaltamide the first FDA-approved targeted pharmacotherapy for essential tremor, a large unmet-need market. A Complete Response Letter would erase most of the company's modeled value. Watch for any FDA AdComm announcement (none currently expected) and for the relutrigine PDUFA on December 27, 2026, which will set the tone for the stock ahead of the ulixacaltamide decision.

Bull case
  • Positive Phase 3 Essential3 program: Both pivotal studies met their primary endpoint (mADL11 at Week 8) with statistical significance (p<0.0001), showing clinically meaningful improvement in daily function.
  • First-to-market opportunity: No FDA-approved targeted pharmacotherapy currently exists for essential tremor, which affects approximately 7 million Americans. Ulixacaltamide would be the first.
  • FDA Breakthrough Therapy Designation (December 2025) signals agency engagement and supports a streamlined review; no advisory committee meeting is currently expected.
Bear case
  • Tolerability concerns: Phase 3 data showed high adverse event-related discontinuation rates, which could limit commercial uptake or prompt FDA labeling restrictions.
  • Competition emerging: Acurex Biosciences received a composition-of-matter patent for CU-00048, another oral T-type calcium channel antagonist for essential tremor, and non-drug wearables like Encora X1 are already FDA-cleared.
  • Premium valuation: At ~$321/share, the stock already prices in substantial approval and commercial success; a Seeking Alpha analysis in June 2026 estimated fair value at $223.73, calling the premium 'unrealistic.'
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 trial reads out positive in early 2027, an NDA filing could follow later in 2027 or 2028, putting potential approval at least 2-3 years away. The drug is not yet filed with the FDA.

vormatrigine Updated Nov 10

What to watch

Watch for the Phase 3 topline data readout for vormatrigine, expected around the estimated primary completion date of January 2027. A positive readout would add a third late-stage pipeline asset to Praxis, while a negative result would be a setback but likely not catastrophic given the company's two lead PDUFA catalysts (relutrigine Dec 27, 2026 and ulixacaltamide Jan 29, 2027). The company's Investor Day on November 12, 2026 may provide additional pipeline updates.

Bull case
  • Focal epilepsy is a large market with significant unmet need; a new oral anti-seizure drug with a favorable profile could capture meaningful share.
  • Praxis has deep expertise in CNS precision neuroscience and a track record of advancing drugs to Phase 3 and NDA filing (relutrigine, ulixacaltamide).
  • The company has $1.3 billion in cash and runway into 2028, providing ample resources to complete the vormatrigine program without financing risk.
Bear case
  • Vormatrigine is a secondary pipeline asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), which together drive most of the company's valuation.
  • The Phase 3 trial is still ongoing with estimated primary completion in January 2027; there is no guarantee of positive topline results, and focal seizure trials have a history of mixed outcomes.
  • PRAX-628, a separate Phase 3 focal seizure program (POWER1), completed in May 2026 with no publicly reported results, which could signal challenges in this indication.
◆ mixed
Impact
PhasePhase 2/3 (registrational)
Time to marketIf EMBRAVE3 topline results are positive, an NDA submission could follow in 2027, with potential FDA approval in 2028 given the Breakthrough Therapy and Rare Pediatric Disease designations that enable accelerated review.

elsunersen Updated Nov 13

What to watch

Watch for EMBRAVE3 registrational topline results, which were expected in 2026 per the company's December 2025 guidance but have not yet been announced. Positive data would support an NDA filing; a miss or delay would push the timeline out significantly. The stock's near-term binary catalysts are relutrigine's PDUFA on December 27, 2026, and ulixacaltamide's PDUFA on January 29, 2027, which will likely dominate price action before elsunersen data emerges.

Bull case
  • EMBRAVE Part A results were strong: 77% sham-adjusted reduction in monthly seizures (p=0.015), 71% of patients achieved >50% seizure reduction, and 57% had at least 28 days of seizure freedom.
  • Elsunersen holds FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations, plus EMA PRIME and Orphan Drug designations, providing regulatory acceleration and potential priority review vouchers.
  • The FDA agreed to a simplified single-arm, baseline-controlled registrational pathway for EMBRAVE3, reducing trial complexity and cost.
Bear case
  • EMBRAVE3 registrational topline results were expected in 2026 but have not yet been reported as of November 2026, suggesting potential enrollment delays or data maturation issues.
  • Elsunersen is a third-priority pipeline asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), so it may receive less management attention and capital allocation.
  • As an antisense oligonucleotide for a rare pediatric epilepsy, the addressable patient population (SCN2A gain-of-function DEE) is very small, limiting peak revenue potential.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet
  • 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks 1 trial

Past FDA events & how the stock moved

9 events
DateDrugEvent1 day5 days
Sep 27, 2026relutriginePriority review+1.7%+5.3%
Sep 27, 2026relutriginePDUFA decision+1.7%+5.3%
Sep 27, 2026relutrigineOrphan drug designation+1.7%+5.3%
Sep 27, 2026relutrigineBreakthrough designation+1.7%+5.3%
Aug 6, 2026relutriginePriority review+13.0%+15.4%
Aug 6, 2026elsunersenBreakthrough designation+13.0%+15.4%
May 7, 2026relutrigineOrphan drug designation−2.4%+2.2%
May 7, 2026relutrigineBreakthrough designation−2.4%+2.2%
Dec 1, 2025ulixacaltamideBreakthrough designation−8.8%+37.9%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
40 mg/day vormatrogine for 12 weeksRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresPhase 3Active not recruiting300Jan 2027
1.0mg/kg/day PRAX-562A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutriginePhase 3Active not recruiting160Dec 2026
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeksDouble-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)Phase 3Completed255May 14, 2026